Paul Schimmel has bought stock on 18 days since Apr 2016

Paul Schimmel, Ph.D., is an accomplished biochemist, entrepreneur, and independent director of aTyr Pharma, Inc., where he has served on the board since September 2005.( A prominent figure in biotechnology, he has co‑founded multiple successful biopharmaceutical companies, including Repligen Corporation, Alkermes, Inc., Cubist Pharmaceuticals, Sirtris Pharmaceuticals, and Alnylam Pharmaceuticals, Inc., and was a founding director of Momenta Pharmaceuticals, Inc.( He has also demonstrated continued confidence in aTyr through substantial open‑market share purchases disclosed in SEC Form 4 filings.(

Schimmel is Professor of Molecular Medicine and of Chemistry at Scripps Research and previously held the John D. and Catherine T. MacArthur Professorship of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology.( He is an elected member of the National Academy of Sciences, National Academy of Medicine, National Academy of Inventors, American Philosophical Society, and American Academy of Arts and Sciences, reflecting his scientific impact and leadership.( He holds a B.A. from Ohio Wesleyan University and a Ph.D. in biochemistry and biophysics from the Massachusetts Institute of Technology.(

Written by Perplexity from public sources.